Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients.

Möbus V, von Minckwitz G, Jackisch C, Lück HJ, Schneeweiss A, Tesch H, Elling D, Harbeck N, Conrad B, Fehm T, Huober J, Müller V, Bauerfeind I, du Bois A, Loibl S, Nekljudova V, Untch M, Thomssen C; German Breast Group (GBG), the AGO Breast Study Group (AGO-B) and NOGGO Study Groups.

Ann Oncol. 2017 Aug 1;28(8):1803-1810. doi: 10.1093/annonc/mdx203.

PMID:
28459941
2.

Side effects of standard adjuvant and neoadjuvant chemotherapy regimens according to age groups in primary breast cancer.

Reinisch M, von Minckwitz G, Harbeck N, Janni W, Kümmel S, Kaufmann M, Elling D, Nekljudova V, Loibl S.

Breast Care (Basel). 2013 Mar;8(1):60-6. doi: 10.1159/000346834.

3.

German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.

von Minckwitz G, Möbus V, Schneeweiss A, Huober J, Thomssen C, Untch M, Jackisch C, Diel IJ, Elling D, Conrad B, Kreienberg R, Müller V, Lück HJ, Bauerfeind I, Clemens M, Schmidt M, Noeding S, Forstbauer H, Barinoff J, Belau A, Nekljudova V, Harbeck N, Loibl S.

J Clin Oncol. 2013 Oct 1;31(28):3531-9. doi: 10.1200/JCO.2012.47.2167. Epub 2013 Aug 26.

PMID:
23980081
4.

Efficacy and patient satisfaction of breast conserving therapy for central breast cancer by the B technique.

Eggemann H, Ignatov A, Elling D, Lampe D, Lantzsch T, Weise M, Costa SD.

Ann Surg Oncol. 2013 Oct;20(11):3438-45. doi: 10.1245/s10434-013-3030-6. Epub 2013 May 25.

PMID:
23709056
5.

The 70-Gene Signature as Prognostic Factor for Elderly Women with Hormone Receptor-Positive, HER2-Negative Breast Cancer.

Hartmann S, Gerber B, Elling D, Heintze K, Reimer T.

Breast Care (Basel). 2012 Feb;7(1):19-24. Epub 2012 Feb 13.

6.

Comparative study of surgical margins and cosmetic outcome in lumpectomy versus segmental resection in breast cancer.

Eggemann H, Ignatov A, Krocker J, Neuss K, Elling D, John J, Costa SD.

Eur Surg Res. 2011;47(4):231-9. doi: 10.1159/000333090. Epub 2011 Nov 2.

PMID:
22056494
7.

Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin Alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study.

Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, Petry KU, Kimmig R, Elling D, Thomssen C, von Minckwitz G, Möbus V, Hinke A, Kümmel S, Budach V, Lichtenegger W, Schmid P.

J Clin Oncol. 2011 Oct 1;29(28):3791-7. doi: 10.1200/JCO.2010.30.4899. Epub 2011 Aug 22.

PMID:
21860000
8.

Influence of a dose-dense adjuvant chemotherapy on sVCAM-1/sICAM-1 serum levels in breast cancer patients with 1-3 positive lymph nodes.

Eggeman H, Stöblen F, Thill M, Korlach S, Schmid P, Lüftner D, Elling D, Taran FA, Kümmel S, Landt S.

Anticancer Res. 2011 Aug;31(8):2617-22.

PMID:
21778313
9.

Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast Cancer.

Bauerfeind I, Elling D, Heinemann V.

Breast Care (Basel). 2010;5(s1):13-15. Epub 2010 Apr 26.

10.

Transvaginal video-assisted cholecystectomy in clinical practice.

Federlein M, Borchert D, Müller V, Atas Y, Fritze F, Burghardt J, Elling D, Gellert K.

Surg Endosc. 2010 Oct;24(10):2444-52. doi: 10.1007/s00464-010-0983-4. Epub 2010 Mar 24.

PMID:
20333406
11.

Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial.

Schmid P, Krocker J, Kreienberg R, Klare P, Kittel K, Sommer H, Heinrich G, Steck T, Lichtenegger W, Elling D, Kümmel S.

Cancer Chemother Pharmacol. 2009 Jul;64(2):401-6. doi: 10.1007/s00280-008-0887-3. Epub 2008 Dec 24.

PMID:
19104816
12.

[Minimal invasive transvaginal right hemicolectomy: report of the first complex NOS (natural orifice surgery) bowels operation using a hybrid approach].

Burghardt J, Federlein M, Müller V, Benhidjeb T, Elling D, Gellert K.

Zentralbl Chir. 2008 Dec;133(6):574-6. doi: 10.1055/s-2008-1076992. Epub 2008 Dec 17. German.

PMID:
19090437
13.

Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials.

Loibl S, von Minckwitz G, Harbeck N, Janni W, Elling D, Kaufmann M, Eggemann H, Nekljudova V, Sommer H, Kiechle M, Kümmel S.

Breast Cancer Res. 2008;10(5):R77. doi: 10.1186/bcr2144. Epub 2008 Sep 16.

14.

Quality of care of VLBW neonates: relationship between unit volume and outcome is different between metropolitan and rural regions.

Jochum F, Schmidt B, Schunk K, Hesse V, Distler B, Laske G, V Moers A, Dombrowsky M, Elling D, Kentenich H, Mendling W, Untch M, Grüning T, Abou-Dakn M.

Acta Paediatr. 2008 Oct;97(10):1470-4. doi: 10.1111/j.1651-2227.2008.00934.x. Epub 2008 Jul 25.

PMID:
18662233
15.

Significant changes in circulating plasma levels of IGF1 and IGFBP3 after conventional or dose-intensified adjuvant treatment of breast cancer patients with one to three positive lymph nodes.

Kümmel S, Eggemann H, Lüftner D, Gebauer N, Bühler H, Schaller G, Schmid P, Kreienberg R, Emons G, Kriner M, Elling D, Blohmer JU, Thomas A.

Int J Biol Markers. 2007 Jul-Sep;22(3):186-93.

PMID:
17922461
16.

Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO.

Sehouli J, Stengel D, Mustea A, Camara O, Keil E, Elling D, Ledwon P, Christiansen B, Klare P, Gebauer G, Schwarz M, Lichtenegger W; Ovarian Cancer Study Group of the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie.

Cancer Chemother Pharmacol. 2008 Feb;61(2):243-50. Epub 2007 Mar 29.

PMID:
17393164
17.

Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer.

Kümmel S, Krocker J, Kohls A, Breitbach GP, Morack G, Budner M, Blohmer JU, Elling D.

Br J Cancer. 2006 May 8;94(9):1237-44.

18.

Changes in the circulating plasma levels of VEGF and VEGF-D after adjuvant chemotherapy in patients with breast cancer and 1 to 3 positive lymph nodes.

Kümmel S, Eggemann H, Lüftner D, Thomas A, Jeschke S, Zerfel N, Heilmann V, Emons G, Zeiser T, Ulm K, Kobl M, Korlach S, Schmid P, Sehouli J, Elling D, Blohmer JU.

Anticancer Res. 2006 Mar-Apr;26(2C):1719-26.

19.

Chemotherapy treatment options for elderly women with breast cancer.

Kümmel S, Elling D, Jeschke S, Schmid P, Thomas A.

Anticancer Res. 2006 Mar-Apr;26(2C):1673-6. Review.

20.

Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older: feasibility and tolerability in a subset of patients in a randomized trial.

Kümmel S, Krocker J, Kohls A, Breitbach GP, Morack G, Budner M, Blohmer JU, Lichtenegger W, Elling D.

Crit Rev Oncol Hematol. 2006 May;58(2):166-75. Epub 2006 Jan 18.

PMID:
16387512
21.

Primary systemic chemotherapy with sequential, dose-dense epirubicin and docetaxel for inoperable, locally advanced inflammatory breast cancer: a phase II study.

Kümmel S, Thomas A, Paepke S, Schwarz M, Heinrich G, Wetzel A, Elling D, Kohls A, Lichtenegger W, Blohmer JU.

Acta Oncol. 2005;44(3):248-54.

PMID:
16076697
22.

Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial.

Schmid P, Krocker J, Jehn C, Michniewicz K, Lehenbauer-Dehm S, Eggemann H, Heilmann V, Kümmel S, Schulz CO, Dieing A, Wischnewsky MB, Hauptmann S, Elling D, Possinger K, Flath B.

Ann Oncol. 2005 Oct;16(10):1624-31. Epub 2005 Jul 19.

PMID:
16030028
23.

Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial.

Schmid P, Krocker J, Schulz CO, Michniewicz K, Dieing A, Eggemann H, Heilmann V, Blohmer JU, Sezer O, Elling D, Possinger K.

Anticancer Drugs. 2005 Jan;16(1):21-9.

PMID:
15613900
24.

Primary chemotherapy with doxorubicin and paclitaxel in patients with early breast cancer: final results of a multicenter phase II study.

Schmid P, Krocker J, Morack G, Heilmann V, Blohmer JU, Michniewicz K, Köhler G, Schaller-Kranz T, Possinger K, Elling D.

J Cancer Res Clin Oncol. 2004 Nov;130(11):657-63. Epub 2004 Aug 20.

PMID:
15322862
25.

Malignant melanoma metastatic to the breast: an interdisciplinary challenge.

Kümmel S, Förster H, Fieldler B, Kretschmer JA, Elling D.

Breast J. 2004 Jul-Aug;10(4):377-9. No abstract available.

PMID:
15239805
26.

Granulosa cell tumor of the ovary: 10 years follow-up data of 65 patients.

Sehouli J, Drescher FS, Mustea A, Elling D, Friedmann W, Kühn W, Nehmzow M, Opri F, Klare P, Dietel M, Lichtenegger W.

Anticancer Res. 2004 Mar-Apr;24(2C):1223-9.

27.

Intraductal component in invasive breast cancer: analysis of 250 resected surgical specimens.

Elling D, Vesper AS, Fiedler B, Martin H, Krocker J.

Breast. 2001 Oct;10(5):405-10.

PMID:
14965615
29.

Gemcitabine combined with cisplatin as first-line treatment in patients 60 years or older with epithelial ovarian cancer: a phase II study.

Bauknecht T, Hefti A, Morack G, Villena-Heinsen C, Wallwiener D, Elling D, Minckwitz GV, Mansouri K, Blatter J, Breitbach GP.

Int J Gynecol Cancer. 2003 Mar-Apr;13(2):130-7.

PMID:
12657112
30.

A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy.

Sehouli J, Stengel D, Oskay G, Camara O, Hindenburg HJ, Klare P, Blohmer J, Heinrich G, Elling D, Ledwon P, Lichtenegger W; NOGGO study group.

Ann Oncol. 2002 Nov;13(11):1749-55.

PMID:
12419747
31.

First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study.

Sehouli J, Stengel D, Elling D, Ortmann O, Blohmer J, Riess H, Lichtenegger W; Ovarian Cancer Study Group of the Nordostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO).

Gynecol Oncol. 2002 May;85(2):321-6.

PMID:
11972395
32.

[Adjuvant chemotherapy of cervix carcinoma--results of a phase II study].

Blohmer JU, Paepke S, Böhmer D, Ernhardt B, Sehouli J, Elling D, Lichtenegger W.

Zentralbl Gynakol. 2001 May;123(5):286-91. German.

PMID:
11449622
33.

[Dose intensified adjuvant chemotherapy in high risk breast carcinoma with 4-9 positive lymph nodes].

Elling D, Krocker J, Kümmel S, Blohmer J, Lichtenegger W, Kohls A, Heinrich J, Quass J, Breitbach P, Köhler U.

Zentralbl Gynakol. 2000;122(4):207-16. German.

PMID:
10795118
34.

[Treatment of vaginal atresia by a cecum transplantation after radical operation for cervical cancer and postoperative radiotherapy].

Elling D, Althaus P, Till A, Liebeskind H.

Zentralbl Gynakol. 2000;122(2):109-11. German.

PMID:
10721192
35.

Detection of BRCA1 and BRCA2 mutations in breast cancer families by a comprehensive two-stage screening procedure.

Spitzer E, Abbaszadegan MR, Schmidt F, Hauser A, Buwitt U, Lauter FR, Pötschick K, Krocker J, Elling D, Grosse R.

Int J Cancer. 2000 Feb 15;85(4):474-81.

36.

Dose- intensified, preoperative and adjuvant chemotherapy in patients with T3- and T4- breast cancer: toxicity, clinical and pathological remission.

Blohmer JU, Paepke S, Kissner L, Elling D, Fleige B, Grineisen Y, Lichtenegger W.

Zentralbl Gynakol. 1999;121(11):522-5.

PMID:
10612219
37.

[Case report of squamous epithelial cancer of the female breast].

Elling D, Krocker J, Martin H, Fiedler B.

Zentralbl Gynakol. 1993;115(11):500-2. German.

PMID:
8296496
38.

[Biochemical changes in cervix mucus in stepwise malignant transformation of cervix epithelium].

Elling D, Bader K.

Zentralbl Gynakol. 1990;112(9):555-60. German.

PMID:
2378186
39.

[Obstetrical data of 11,874 deliveries at a university clinic of a developing country].

Elling D.

Zentralbl Gynakol. 1990;112(6):369-75. German.

PMID:
2371799
40.

[Prognostic significance of the length of the uterus, depth of infiltration and grading of endometrium cancer].

Elling D, Schildhaus I, Götze W, Bartel U.

Zentralbl Gynakol. 1990;112(2):75-9. German.

PMID:
2316298
41.

[Do tumor markers provide a diagnostic gain?].

Elling D.

Zentralbl Gynakol. 1990;112(19):1193-5. German. No abstract available.

PMID:
2267872
42.

[Detection of human papillomavirus (HVP) 16/18 infections of the vaginal uterine cervix in females before and following conisation].

Götze W, Jantschak J, Kohls A, Elling D, Schildhaus I.

Zentralbl Gynakol. 1990;112(14):875-81. German.

PMID:
2176023
43.

[Endocrine cancer of the uterine cervix].

Bartho S, Gottschalk J, Elling D.

Zentralbl Gynakol. 1989;111(8):533-6. German.

PMID:
2741594
44.

[The value of CA 125 determination in the serum of patients with ovarian cancer].

Bartel U, Johannsen B, Elling D.

Zentralbl Gynakol. 1989;111(5):301-9. German.

PMID:
2728673
45.
46.

[Initial experiences with CA-15-3 determination in the serum of patients with breast cancer].

Bartel U, Johannsen B, Reiss H, Elling D.

Zentralbl Gynakol. 1989;111(21):1417-24. German.

PMID:
2557715
47.
48.

[3-year analysis of gynecologic neoplasms treated at the Central Maputo Hospital].

Elling D, Ching C.

Zentralbl Gynakol. 1988;110(11):667-70. German.

PMID:
3414209
49.
50.

[Genital schistosomiasis--diagnosis and therapy].

Elling D, Kupferschmidt HG.

Zentralbl Gynakol. 1988;110(11):671-6. German.

PMID:
3137734

Supplemental Content

Loading ...
Support Center